ReviewBlood reviews2016
Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.
Review in Blood reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisTrial
- Diagnostic and Prognostic Significance of Peripheral Blood RASSF1A, P16, and PTGER4 Gene Methylation in Adult Acute Leukemia.European journal of haematology · 2026Article
- Fibrin-Based Biomaterials in Wound Healing and Soft Tissue Regeneration: Biological Mechanisms and Clinical Applications.Gels (Basel, Switzerland) · 2026Review
- Factor XIII deficiency: an updated approach to diagnosis and management.Frontiers in medicine · 2026Review
- Revision and update of the position paper on the management of notifications of donors with Creutzfeldt-Jakob disease in Italy.Blood transfusion = Trasfusione del sangue · 2025Article
- PMCA for ultrasensitive detection of prions and to study disease biology.Cell and tissue research · 2023Review
- Parvovirus B19 DNA and antibodies in Chinese plasma donors, plasma pools and plasma derivatives.PeerJ · 2023Article
- Anti-Viral Photodynamic Inactivation of T4-like Bacteriophage as a Mammalian Virus Model in Blood.International journal of molecular sciences · 2022Article
- Challenges in Metabolomics-Based Tests, Biomarkers Revealed by Metabolomic Analysis, and the Promise of the Application of Metabolomics in Precision Medicine.International journal of molecular sciences · 2022Review
- The 4-Year Experience with Implementation and Routine Use of Pathogen Reduction in a Brazilian Hospital.Pathogens (Basel, Switzerland) · 2021Article
- Review
- Photodynamic Inactivation ofAntibiotics (Basel, Switzerland) · 2019Article
- Application of PMCA to screen for prion infection in a human cell line used to produce biological therapeutics.Scientific reports · 2019Article
- Pathogens transmitted in red blood cell transfusions: An up-to-date table.Proceedings (Baylor University. Medical Center) · 2018Review
- First detection of human hepegivirus-1 (HHpgV-1) in Iranian patients with hemophilia.Scientific reports · 2018Article
- Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.Blood transfusion = Trasfusione del sangue · 2017Review
- Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?Annals of hematology · 2017Review
- Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk.Transfusion medicine reviews · 2017Review
- Epidemiological Profile of Hemophilia in Baghdad-Iraq.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogen safety of blood/plasma-derived products has historically been a subject of significant concern to the medical community. Measures such as donor selection and blood screening have contributed to increase the safety of these products, but pathogen transmission does still occur. Reasons for this include lack of sensitivity/specificity of current screening methods, lack of reliable screening tests for some pathogens (e.g. prions) and the fact that many potentially harmful infectious agents are not routinely screened for. Methods for the purification/inactivation of blood/plasma-derived products have been developed in order to further reduce the residual risk, but low concentrations of pathogens do not necessarily imply a low level of risk for the patient and so the overall challenge of minimising risk remains. This review aims to discuss the variable level of pathogenic risk and describes the current screening methods used to prevent/detect the presence of pathogens in blood/plasma-derived products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.